2.97 USD
▼-0.30-9.17%
盘后 3.00 +1.01%
2026-09-15
市值
$212.84M
市盈率
—
EPS
-0.40
股息率
—
52 周区间
1.30 – 4.85
成交量
626.11K
Beta
0.56
目标价
9.91
52W 低 1.3052W 高 4.85
价格走势
公司简介
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ...